期刊文献+

恶性胶质瘤治疗后影像学评估的研究进展 被引量:3

下载PDF
导出
摘要 目前,恶性胶质瘤标准的治疗方案为手术后替莫唑胺同步放疗联合辅助化疗,近年来抗血管生成药物也被用于胶质瘤的治疗,这些治疗方法在一定程度改善了病人预后;但是恶性胶质瘤仍会复发,恶性胶质瘤的治疗效果和病情进展需要正确评价,其中影像学检查是最直观的评价方法。目前临床上应用最广的影像学评价标准是Macdonald标准,随着假性进展和假性反应的发现,国外相应制定了新的RANO标准。本文就恶性胶质瘤治疗后的影像学评估进行综述。
出处 《中国微侵袭神经外科杂志》 CAS 2014年第10期476-478,共3页 Chinese Journal of Minimally Invasive Neurosurgery
  • 相关文献

参考文献16

  • 1Reardon DA, Galanis E, DeGroot JF, et ol. Clinical trial end points for high-grade glioma: the evolving landscape [J]. Neuro Oncol, 2011, 13(3): 353-361.
  • 2陈红燕,戴建平,李少武,艾林,孙学进,高培毅,陈宝龙.磁共振扩散张量成像在鉴别胶质瘤不同成分中的应用[J].中国微侵袭神经外科杂志,2012,17(5):193-195. 被引量:1
  • 3Chinot OL, Macdonald DR, Abrey LE, et ol. Response assessment criteria for glioblastoma: practical adaptatior and implementation in clinical trials of antiangiogenic therapy [J]. Curr Neurol Neurosci Rep, 2013, 13(5): 347.
  • 4Wen PY, Norden AD, Drappatz J, et al. Response assess.ment challenges in clinical trials of gliomas [J]. Curr Oncol Rep, 2010, 12(1): 68-75.
  • 5Lutz K, Radbruch A, Wiestler B, et al. Neuroradiological response criteria for high-grade gliomas [J]. Clin Neuro- mdiol, 2011, 21(4): 199-205.
  • 6李守巍,江涛.高级别胶质瘤治疗反应评判的新标准[J].中华神经外科杂志,2013,29(11):1180-1182. 被引量:7
  • 7Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group [J]. J Clin Oncol, 2010, 28(11): 1963-1972.
  • 8Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically deliver- ed therapies for gliomas: Response Assessment in Neuro- Oncology (RANO) Working Group [J]. Neurosurgery, 2012, 70(1): 234-244.
  • 9Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma [J]. Cancer J, 2012, 18(1): 26- 31.
  • 10于同刚,潘力,戴嘉中,冯晓源.脑胶质瘤放射治疗后的假性进展[J].中国微侵袭神经外科杂志,2010,15(1):41-43. 被引量:8

二级参考文献25

共引文献19

同被引文献31

  • 1Fatterpekar GM,Galheigo D,Narayana A,et al.Treatmentrelated change versus tumor recurrence in high grade glioma:a diagnostic conundrum-use of dynamic susceptibility contrast-enhanced(DSC)perfusion MRI[J].Am J Roentgenol,2012,198(1):19-26.
  • 2Wong CS,Van der Kogel AJ.Mechanisms of radiation injury to the central nervous system:implication for neuroprotection[J].Mol Interv,2004,4(5):273-284.
  • 3Caroline I,Rosenthal MA.Imaging modalities in high grade glioma:pseudoprogression,recurrence,or necrosis[J]?J Clin Neurosci,2012,19(5):633-637.
  • 4Kitange GJ,Carlson BL,Mladek AC,et al.Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model[J].J Neurooncol 2009,92(1):23-31.
  • 5Zhang J,Stevens MF,Laughton CA,et al.Acquired resistance to temozolomide in glioma cell lines:molecular mechanisms and potential translational applications[J].Oncology,2010,78(2):103-114.
  • 6Kumar AJ,Leeds NE,Fuller GN,et al.Malignant gliomas:MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment[J].Radiology,2000,217(2):377-384.
  • 7Alexiou GA,Tsiouris S,Kyritsis AP,et al.Glioma recurrence versus radiation necrosis:accuracy of current imaging modalities[J].J Neurooncol,2009,95(1):1-11.
  • 8Jain RK,Tong RT,Munn LL.Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension,peritumor edema,and lymphatic metastasis:insights from a mathematical model[J].Cancer Res,2007,67(6):2729-2735.
  • 9Chinot OL,Macdonald DR,Abrey LE,et al.Response assessment criteria for glioblastoma:practical adaptation and implementation in clinical trials of antiangiogenic therapy[J].Curr Neurol Neurosci Rep,2013,13(5):347.
  • 10De Bonis P, Anile C, Pompucci A, et al . Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblas- toma[J]. Acta Neurochir (Wien), 2012, 154(8) :1371-1378.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部